APRESAZIDE COLOR, SIZE & SHAPE CASE: BOLAR SEEKING TO EXPEDITE APPEAL
APRESAZIDE COLOR, SIZE & SHAPE CASE: BOLAR SEEKING TO EXPEDITE APPEAL of a NJ federal court's permanent injunction prohibiting it from employing the same trade dress used by Ciga-Geigy for the hydralazine hydrochlorothiazide combo. On March 5, Bolar asked the Third Circuit to affirm NJ Federal Judge Sarokin's permanent order so that the generic firm can seek to return the case to the Supreme Court. Bolar's suggestion to the Third Circuit followed the Supreme Court's denial, on the same day, of the firm's petition for certiorari relating to a preliminary injunction issued by Sarokin in the fall of 1982. While the appeal of the preliminary injunction was moving through the Third Circuit to the Supreme Court, Sarokin converted the original order to a permanent injunction. Bolar restarted the appeals process on the permanent injunction, and now wants the Third Circuit to reaffirm its decision in the belief that the Supreme Court will be more likely to accept the case under a permanent injunction. The high court rarely accepts review of preliminary injunction. The case is significant because it is being considered under a New Jersey state law and section 43(a) of the Federal Lanham Act, which addresses unfair competition practices. An earlier "look-alike" case which reached the Supreme Court, the Ives Cyclospasmol suit, was decided under section 33 of the Lanham Act which deals with the narrower issue of trademark infringement. In that case, the Supreme Court ruled that Inwood Labs was not responsible for "passing off" its products for Ives' drug. The current case could establish whether generic use of brand name trade dress per se is unfair.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth